Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis.

Chang ChuShufei ZengAhmed A HasanCarl-Friedrich HocherBernhard K KrämerBerthold Hocher

Published in: British journal of clinical pharmacology (2020)

ACEIs reduce the risk of getting infected with the SARS-CoV-2 virus. Blocking the RAAS may decrease all-cause mortality in COVID-19 patients. ACEIs also reduce the risk of non-COVID pneumonia. All-cause mortality due to non-COVID pneumonia is reduced by ACEI and potentially by ARBs.

Keyphrases

sars cov
respiratory syndrome coronavirus
angiotensin ii
angiotensin converting enzyme
coronavirus disease
community acquired pneumonia
intensive care unit